PRTN3 and rheumatoid arthritis: This is below 0.6, the change considered significant in the EULAR criteria [33] but similar to the difference in ΔDAS28 between seropositive and seronegative RA patients treated with rituximab at six months (0.3 for RF and 0.6 for ACPA according to a meta-analysis of patient registers [5]; and 0.35 for seropositive patients from a meta-analysis of clinical trials [6]), which is considered sufficient to help in the choice of treatment.